期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

伊马替尼血药浓度检测的意义 被引量：7

Determination of imatinib in human plasma and its significance
原文传递
导出
摘要 伊马替尼已作为慢性粒细胞白血病（CML）的一线治疗药物，疗效令人鼓舞。伊马替尼的血药浓度与CML患者的生存期及缓解率相关。其血浆浓度主要受α1-酸性糖蛋白（AGP）及改变细胞色素P450（CYP3A4）酶活性的影响。监测伊马替尼血药浓度有助于指导CML的临床治疗。 As the first line of therapy for chronic myeloid leukemia, the outcome of imatinib is encouraging. The plasma concentration of imatinib is correlated with remission rate and survival, and affected by α1 acid glycoprotein（AGP） and those drugs which will change the activities of cytochrome P450（CYP3A4）. It is conductive for the treatment of CML by monitoring the plasma concentration of imatinib.
作者 钟健生(综述) 孟凡义(审校)
机构地区 南方医科大学南方医院血液科
出处 《白血病．淋巴瘤》 CAS 2010年第1期61-64,共4页 Journal of Leukemia & Lymphoma
关键词 伊马替尼 血药浓度 意义 Imatinib Concentration Significance
分类号 R979.1 [医药卫生—药品] R969.1 [医药卫生—药学]
  • 相关文献

参考文献39

  • 1Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res, 2002, 8: 935-942. 被引量：1
  • 2Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood, 2008, 111: 1039-1043. 被引量：1
  • 3Palandri F, Castagnetti F, Alimena G, et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica, 2009, 94: 205-212. 被引量：1
  • 4Druker BJ, Guilhot F, O" Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 2006, 355: 2408-2417. 被引量：1
  • 5Bianchini M, De Brasi C, Gargallo P, et al. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients. Eur J Haematol, 2008. 被引量：1
  • 6Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 2001, 344: 1031-1037. 被引量：1
  • 7Deininger MW, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL- positive cells. Blood, 1997, 90: 3691-3698. 被引量：1
  • 8Colombat M, Fort M P, Chollet C, et al. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment. Haematologica, 2006, 91: 162-168. 被引量：1
  • 9Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood, 2007, 109: 3496-3499. 被引量：1
  • 10Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmaeokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood, 2008, 111: 4022-4028. 被引量：1

同被引文献55

  • 1O'Brien S, Berman E, Borqhael H, et al. NCCN Clinical practice guidelines in oncology: chronic myelogenous leukemia. J Nati Compr Canc Netw, 2009, 7: 984-1023. 被引量：1
  • 2Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Eng J Med, 2006, 355: 2408-2417. 被引量：1
  • 3Walz C, Sattler M. Novel targeted therapies to overcome inmtinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol, 2006, 57: 145-164. 被引量：1
  • 4Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to ST1- 571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 2001, 293: 876-880. 被引量：1
  • 5Mahon FX, Belloc F, Lagarde V, et al. MDR1 gent overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood, 2003, lOh 2368-2373. 被引量：1
  • 6Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood, 2000, 96: 1070-1079. 被引量：1
  • 7Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard- dose imatinib in chronic myeloid leukemia. Blood, 2007, 109: 3496- 3499. 被引量：1
  • 8Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet, 2005, 44: 879-894. 被引量：1
  • 9White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood, 2007, 110: 4064-4072. 被引量：1
  • 10Forrest DL, Trainor S, Brinkman RR, et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy hut not trough imatinib plasma levels. Leuk Res, 2009, 33:271-275. 被引量：1

引证文献7

二级引证文献15

白血病．淋巴瘤
2010年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部